"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu

Condition(s) studied

Study summary

Hepatitis B virus (HBV) infection remains one of the most serious health problems worldwide. Patients with chronic HBV infection are at an increased risk for developing hepatic cirrhosis, hepatocellular carcinoma and even death. Although some predictive factors of the outcome of chronic HBV infection were identified, more precisely determine the factors which are associated with the outcome in non-selected patients with chronic HBV infection are still needed. The investigators purpose is to constitute a observational cohort of non-selected Chinese patients to create a database of epidemiological, clinical, biological, virological, immunologic and therapeutic parameters, in order to determine factors associated with the outcome of chronic HBV infection.

Eligibility

Primary outcome measure(s)

• Number of participants with antigen loss (HBeAg and HBsAg loss) — 20 years
• Cirrhosis — 20 years
• Hepatic decompensation — 20 years
  Development of hepatic decompensation will be defined by any of the following events: (1) Ascites or hepatic hydrothorax; (2)Variceal or portal hypertensive bleeding; (3)Hepatic encephalopathy
• Hepatocellular carcinoma (HCC) — 20 years
  The diagnosis of HCC will be made using the American Association for the Study of Liver Disease criteria.
• Death — 20 years
  Date and cause of death will be recorded.

Trial sites (6)

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China